Last updated: 07/29/2020 03:50:14
Refresh Nucala 12 months pre/post
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Update to Asthma Exacerbations and Healthcare Utilization in Patients Receiving Nucala in an Employer Claims Database
Trial description: Mepolizumab is a humanized interleukin-5 antagonist monoclonal antibody administered by subcutaneous injection by a health care professional via subcutaneous injection. Asthma is a common chronic respiratory disorder that effects millions of children and adults in the United States (US). Mepolizumab has been shown to reduce the frequency of asthma exacerbations in subjects with severe asthma in clinical trials. This is a retrospective cohort study which will compare rates of asthma exacerbations and costs associated with those exacerbations among subjects receiving mepolizumab. Medical or pharmacy claim between 1-November-2015 and 31-March-2017 with a Healthcare Common Procedure Coding System (HCPCS) or National Drug Code (NDC) code indicating administration of mepolizumab is part of the database. This study will try to analyze performance of mepolizumab in the market which will include effect on rate of asthma exacerbation and the associated costs. The data for the study will be derived from IBM Watson Health’s Research Databases.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Total number of asthma exacerbations per subjects
Timeframe: Up to 12 months post-dose of mepolizumab
Percentage of subjects with asthma exacerbations
Timeframe: Up to 12 months post-dose of mepolizumab
Percentage of subjects with exacerbation resulting in a hospitalization
Timeframe: Up to 12 months post-dose of mepolizumab
Total number of any exacerbation
Timeframe: Up to 12 months post-dose of mepolizumab
Total number of exacerbations result in hospitalization
Timeframe: Up to 12 months post-dose of mepolizumab
Rate of exacerbation
Timeframe: Up to 12 months post-dose of mepolizumab
Secondary outcomes:
Total cost related to asthma exacerbation post administration of mepolizumab
Timeframe: Up to 12 months post-dose of mepolizumab
Number of claims with asthma exacerbation related costs post administration of mepolizumab
Timeframe: Up to 12 months post-dose of mepolizumab
Interventions:
Drug: Mepolizumab
Enrollment:
0
Observational study model:
Cohort
Primary completion date:
2019-21-02
Time perspective:
Retrospective
Clinical publications:
Llanos JP, Ortega H, Bogart M, Packnett E, Manjelievskaia J, Bell C, Hahn B. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;2020(13):77-87
DOI: 10.2147/JAA.S236609
Medical condition
Asthma
Product
mepolizumab
Collaborators
IBM Watson Health
Study date(s)
December 2018 to February 2019
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
12+ years
Accepts healthy volunteers
No
- Inclusion Criteria
- Medical or pharmacy claim between November 1, 2015 and March 31, 2017 with a HCPCS or NDC code indicating administration of mepolizumab. The date of first mepolizumab administration (index date).
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion Criteria
- Medical or pharmacy claim between November 1, 2015 and March 31, 2017 with a HCPCS or NDC code indicating administration of mepolizumab. The date of first mepolizumab administration (index date).
- 12 months of continuous enrollment with medical and pharmacy benefits in the year prior to the index date (baseline period).
- 12 months of continuous enrollment with medical and pharmacy benefits including and following the index date (follow-up period).
- A diagnosis of asthma during the 12-month baseline period.
- At least 12 years of age as of index.
- A minimum of 2 doses of mepolizumab in the first 180 days of the 12-month follow-up period. Exclusion Criteria
- Evidence of mepolizumab use during the 12-month baseline period.
- Evidence of omalizumab use during the 12-month baseline or 12-month follow-up periods.
- Evidence of reslizumab use during the 12-month baseline or 12-month follow-up periods.
- Evidence of benralizumab use during the 12-month baseline or 12-month follow-up periods.
- Evidence of dupilumab use during the 12-month baseline or 12-month follow-up periods.
- Subjects with missing demographic information will be excluded from the study.
Trial location(s)
No location data available.
Study documents
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2019-21-02
Actual study completion date
2019-21-02
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website